Growth-inhibitory activity of melatonin on murine foregastric carcinoma cells in vitro and the underlying molecular mechanism

Anatomical Record

Volumn 296, Issue 6, 2013, Pages 914-920

  Xu, Li ^a   Liu, Hui ^a   Zhang, Hui ^a   Wang, Ri Xiong ^a   Song, Jun ^a   Zhou, Rui Xiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bax; Bcl 2; Gastric cancer; Melatonin; MT1 receptor; MT2 receptor; P21

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; MELATONIN; MESSENGER RNA; PROTEIN BAX; PROTEIN P21;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA;

ANIMALS; ANTIOXIDANTS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; MELATONIN; MICE; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RNA, MESSENGER; STOMACH NEOPLASMS;

ANIMALIA; MURINAE;

EID: 84878106564     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22689     Document Type: Article

References (35)

1. Adams JM, Cory S. 2007. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19:488-496.
2. Blask DE, Dauchy RT, Sauer LA, Krause JA. 2004. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25:951-960.
3. Carbajo-Pescador S, Martin-Renedo J, Garcia-Palomo A, Tuñón MJ, Mauriz JL, González-Gallego J. 2009. Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells. J Pineal Res 47:330-338.
4. Carrillo-Vico A, Lardone PJ, Fernandez-Santos JM, Martín-Lacave I, Calvo JR, Karasek M, Guerrero JM. 2005. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab 90:992-1000.
5. Claustrat B, Brun J, Chazot G. 2005. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9:11-24.
6. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C, Sánchez-Barceló EJ. 2006. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118:274-278.
7. Crew KD, Neugut AI.2006. Epidemiology of gastric cancer. World J Gastroenterol 12:354-362.
8. Cuzzocrea S, Reiter RJ. 2002. Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2:153-165.
9. Dauchy RT, Blask DE, Dauchy EM, Davidson LK, Tirrell PC, Greene MW, Tirrell RP, Hill CR, Sauer LA. 2009. Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. J Pineal Res 47:32-42.
10. Dauchy RT, Dauchy EM, Davidson LK, Krause JA, Lynch DT, Tirrell PC, Tirrell RP, Sauer LA, Van der Riet P, Blask DE. 2007. Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids. Comp Med 57:377-382.
11. Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. 2000. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 20:21-24.
12. Girgert R, Hanf V, Emons G, Gründker C. 2009. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 47:23-31.
13. Gong Y, Deng S, Zhang M, Wang G, Minuk GY, Burczynski F. 2002. A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells. Br J Cancer 86:625-629.
14. Harada H, Grant S. 2003. Apoptosis regulators. Rev Clin Exp Hematol 7:117-138.
15. Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, Xu C, Chen Z. 2010. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 37:515-520.
16. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. 1993. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361:365-369.
17. Kadekaro AL, Andrade LN, Floeter-Winter LM, Rollag MD, Virador V, Vieira W, Castrucci AM. 2004. MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 36:204-211.
18. Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. 2000. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 28:227-233.
19. Konturek PC, Konturek SJ, Burnat G, Brzozowski T, Brzozowska I, Reiter RJ. 2008. Dynamic physiological and molecular changes in gastric ulcer healing achieved by melatonin and its precursor L-tryptophan in rats. J Pineal Res 45:180-190.
20. Lardone PJ, Carrillo-Vico A, Naranjo MC, De Felipe B, Vallejo A, Karasek M, Guerrero JM. 2006. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 206:273-279.
21. Leon-Blanco MM, Guerrero JM, Reiter RJ, Pozo D. 2004. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett 216:73-80.
22. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. 1993. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 79:401-404.
23. Liu H, Xu L, Wei JE, Xie MR, Wang SE, Zhou RX. 2011. Role of CD41CD251 regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat Rec 294:781-788.
24. Martín-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andrés O, González P, González-Gallego J. 2008. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 45:532-540.
25. Motilva V, Cabeza J, Alarcón de la Lastra C. 2001. New issues about melatonin and its effects on the digestive system. Curr Pharm Des 7:909-931.
26. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP. 2008. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85:335-353.
27. Saez MC, Barriga C, Garcia JJ, Rodriguez AB, Masot J, Duran E, Ortega E. 2005. Melatonin increases the survival time of animals with untreated mammary tumours: neuroendocrine stabilization. Mol Cell Biochem 278:15-20.
28. Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ. 2005. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63:29-43.
29. Saito M, Korsmeyer SJ, Schlesinger PH. 2000. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat Cell Biol 2:553-555.
30. Sauer LA, Dauchy RT, Blask DE. 2001. Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life Sci 68:2835-2844.
31. Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF. 1999. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 27:183-192.
32. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. 2008. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7:189-203.
33. Tam CW, Mo CW, Yao KM, Shiu SY. 2007. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 42:191-202.
34. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. 2002. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 23:298-302.
35. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. 2003. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 72:2183-2198.